Company news

Cue Biopharma, Inc. news in 2025

Cue Biopharma, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Cue Biopharma Announces Pricing of $10 Million Public Offering

December 19, 2025

Cue Biopharma Announces Proposed Public Offering

December 18, 2025

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 12, 2025

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

November 6, 2025

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

September 29, 2025

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

August 21, 2025

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

August 13, 2025

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 12, 2025

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

July 16, 2025

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

July 1, 2025

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

June 24, 2025

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 12, 2025

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 8, 2025

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

May 5, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

April 14, 2025

Cue Biopharma to Host Business Update Call and Webcast

April 14, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

April 14, 2025

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

March 31, 2025

Calls in 2025

Decks in 2025